Ceftobiprole in Hospital Acquired Pneumonia
Pneumonia
About this trial
This is an interventional treatment trial for Pneumonia focused on measuring Ceftobiprole medocaril, Nosocomial Pneumonia, Ventilator-Associated Pneumonia, Cephalosporins, Methicillin-Resistant Staphylococcus Aureus
Eligibility Criteria
Inclusion Criteria: Patients suffering from nosocomial pneumonia or ventilator-associated pneumonia Female patients must be postmenopausal for at least 1 year, surgically sterile, or practicing an effective method of birth control, before entry and throughout the study, and have a negative serum or urine pregnancy test at the screening Exclusion Criteria: Known or suspected hypersensitivity to any related antibiotic medications Any known or suspected condition or concurrent treatment that would be contraindicated by the prescribing information Treatment with any investigational drug within 30 days before enrollment Prior enrollment to this study
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
001
002
ceftobiprole plus placebo ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days
linezolid plus ceftazidime linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days